Sreekanth K. Chaguturu - Nov 29, 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Sreekanth K. Chaguturu
Stock symbol
CVS
Transactions as of
Nov 29, 2022
Transactions value $
-$44,589
Form type
4
Date filed
12/1/2022, 04:23 PM
Previous filing
Sep 2, 2022
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Tax liability -$44.6K -442 -13.24% $100.88 2.9K Nov 29, 2022 Direct F1
holding CVS Common Stock (RSU) 354 Nov 29, 2022 Direct F2
holding CVS Common Stock (RSU) 2.15K Nov 29, 2022 Direct F3
holding CVS Common Stock (RSU) 1.26K Nov 29, 2022 Direct F4
holding CVS Common Stock (RSU) 2.09K Nov 29, 2022 Direct F5
holding CVS Common Stock (RSU) 2.78K Nov 29, 2022 Direct F6
holding CVS Common Stock (RSU) 6.18K Nov 29, 2022 Direct F7
holding CVS Common Stock (RSU) 12.7K Nov 29, 2022 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 4.96K Nov 29, 2022 Common Stock 4.96K $75.27 Direct F9
holding CVS Stock Option 9.58K Nov 29, 2022 Common Stock 9.58K $58.34 Direct F10
holding CVS Stock Option 9.5K Nov 29, 2022 Common Stock 9.5K $74.30 Direct F11
holding CVS Stock Option 13K Nov 29, 2022 Common Stock 13K $101.09 Direct F12

Explanation of Responses:

Id Content
F1 Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award.
F2 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
F3 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F4 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F5 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
F6 Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
F7 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
F8 Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
F9 Option became exercisable in four equal annual installments, commencing 11/29/2020.
F10 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F11 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F12 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.